P15.03: Ultrasonographic evaluation of the effects of dienogest on volume and features of ovarian endometriomas

The purpose of this prospective study was to evaluate the changes in volume and in ultrasound features of ovarian endometriomas after treatment with dienogest. Twenty-seven patients, in childbearing age, were selected based on prescription of hormonal therapy, dienogest, at the dose 2 mg/day, following ultrasound diagnosis of one or more endometriomas. All the patients were revaluated by transvaginal ultrasound after a six-month continuous dienogest treatment (2 mg/day). The volume and echogenicity of the cystic fluid were recorded in both occasions. On 13 patients an additional transvaginal ultrasound was performed after 3 months of treatment. We enrolled twenty-four premenopausal patients. After six months of treatment a significant reduction of the mean volume of endometriomas was observed. After treatment the cystic fluid content showed changes in echogenicity, appearing more echogenic and with hyperechoic spots in 62% of the cases. Treatment with dienogest not only reduces the symptoms related to endometriosis but also the volume of endometriotic ovarian lesions. Three months of treatment are insufficient to achieve this effect.